Hangzhou Tigermed Consulting Co., Ltd

Equities

300347

CNE100001KV8

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
52.25 CNY +2.63% Intraday chart for Hangzhou Tigermed Consulting Co., Ltd +2.09% -4.95%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hangzhou Tigermed Consulting Co., Ltd Announces Final Dividend for the Year Ended December 31, 2023, Payable on 31 July 2024 CI
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes CI
China Healthcare Stocks Rally on Hopes for Government Support DJ
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares RE
Nomura Downgrades Hangzhou Tigermed Consulting to Neutral From Buy, Adjusts Price Target to 49.61 Yuan From 75.72 Yuan MT
Nomura Downgrades Tigermed to Neutral From Buy, Adjusts Price Target to HK$32.69 From HK$57.77 MT
Hangzhou Tigermed Consulting Plans Up to 1 Billion Yuan Share Repurchase; Shares Jump 4% MT
Hangzhou Tigermed Consulting Co., Ltd announces an Equity Buyback for CNY 1,000 million worth of its shares. CI
Hangzhou Tigermed Consulting Co., Ltd authorizes a Buyback Plan. CI
Nomura Adjusts Hangzhou Tigermed Consulting' Price Target to 75.72 Yuan from 83.50 Yuan, Keeps at Buy MT
Nomura Adjusts Hangzhou Tigermed Consulting' Price Target to HK$57.77 from HK$64.46, Keeps at Buy MT
Hangzhou Tigermed Consulting's Profit Up 19% in Q3 MT
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tigermed Consulting's Profit Jumps 16.5% in H1 MT
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tigermed Officially Opens International Headquarters in Hong Kong CI
Bioclub announced that it has received funding from Hangzhou Tigermed Consulting Co., Ltd CI
Nomura Adjusts Tigermed to Buy From Neutral, Adjusts Price Target to 83.50 Yuan From 91.67 Yuan MT
Nomura Upgrades Tigermed to Buy From Neutral, Adjusts Price Target to HK$64.46 From HK$79.47 MT
Hangzhou Tigermed Consulting Co., Ltd. Announces Final Profit Distribution Plan Implementation (A Shares) for 2022, Payable on 07 July 2023 CI
Hangzhou Tigermed Consulting Co. Ltd. Proposes Ordinary Final Dividend for the Year Ended December 31, 2022, Payable on 07 July 2023 CI
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $63.25 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd., Beijing Konruns Pharmaceutical Co.,Ltd., Hangzhou Tigermed Consulting Co., Ltd, Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd., Yingke Innovation Asset Management Co., Ltd. CI
Hangzhou Tigermed Consulting Names Chairman, Other Officials MT
Hangzhou Tigermed Consulting Co. Ltd. Announces Ordinary Final Dividend for the Year Ended December 31, 2022, Payable on 21 July 2023 CI
Chart Hangzhou Tigermed Consulting Co., Ltd
More charts
Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows: - provision of clinical trial services and related technological services (51.8%); - provision of clinical research consulting services (48.2%). China accounts for 46% of sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
52.25 CNY
Average target price
66.39 CNY
Spread / Average Target
+27.06%
Consensus
  1. Stock
  2. Equities
  3. Stock Hangzhou Tigermed Consulting Co., Ltd - Shenzhen S.E.
  4. News Hangzhou Tigermed Consulting Co., Ltd
  5. Hangzhou Tigermed Consulting : Profit Jumps 35.1% on Higher Investment Income in January-September